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In Australia, Canada, New Zealand, and the United States
indigenous people have high rates of chronic kidney disease
but poor access to effective therapies. To more fully define
these issues, we compared the demographics of renal
transplantation of indigenous patients in these 4 countries.
Data encompassing 312,507 indigenous and white patients
(18–64 years of age) who initiated dialysis within an 11-year
period ending in 2005 were obtained from each country’s
end-stage kidney disease registry. By the study’s end, 88,173
patients had received a renal transplant and 130,261 had
died without receiving such. Compared with white patients,
the adjusted likelihood of receiving a transplant for
indigenous patients was significantly lower in Australia
(hazard ratio (HR) 0.23), Canada (HR 0.34), New Zealand (HR
0.23), and the United States (HR 0.44). In all four countries,
indigenous patients had significantly longer overall median
waiting times compared to white patients. Our study shows
that despite marked differences in health care delivery
systems, indigenous patients are less likely than white
patients to receive a renal transplant in these countries.
Understanding and addressing barriers to renal
transplantation of indigenous patients remains an
important concern.
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In Australia, Canada, New Zealand, and the United States,
indigenous people experience substantially worse health
outcomes than non-indigenous people.1 Over the last two
decades, the prevalence of chronic disease among indigenous
people has risen dramatically, with a well documented excess
burden of diabetes, heart disease, and kidney disease.1–5 In
Australia, New Zealand, and Canada, indigenous people
experience more than twice the prevalence of end-stage
kidney disease (ESKD) than whites. Similarly, in the United
States, American Indians and Alaskan Natives have a 2.5
percent higher prevalence of ESKD as compared with white
Americans.1–8 Systematic differences in rates of utilization of
primary care and preventive services contribute to poorer
outcomes.9 Indigenous patients also have unequal access to
diagnostic and therapeutic procedures that are used to treat
chronic diseases, such as angiography, percutaneous coronary
interventions, and coronary artery bypass grafting for
coronary artery disease, when compared with non-indigenous
patients.10–12
Kidney transplantation is considered as the optimal
treatment for most non-elderly patients with ESKD, conferring
a significant survival advantage and improvement in quality of
life over dialysis therapy.13,14 However, analyses from indivi-
dual countries, some regional in scope and others with limited
adjustment for confounding factors, have shown that indigen-
ous patients have low rates of kidney transplantation.15–18 In
this study, we compared renal transplant utilization by
indigenous patients across four countries – Australia, Canada,
New Zealand, and the United States – that have distinctly
different health care systems. Our study had two primary
objectives: (1) To assess transplantation rates (overall, and
from deceased and living donors) among indigenous and white
patients while controlling for comparable demographic and
clinical variables across all four countries; and (2) to compare
median transplant waiting times (by donor type) among
indigenous and white patients in each country.
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RESULTS
The cohort consisted of 312,507 patients from ages 18 to 64
years, including 9837 from Australia, 17,986 from Canada,
2771 from New Zealand, and 281,913 from the United States.
By 31 December 2006, 28% of the cohort (88,173 patients)
had received a renal transplant, and 41.6% (130,261) had
died without receiving a transplant.
The characteristics of indigenous and white patients
beginning maintenance dialysis in each country are depicted
in Table 1. Indigenous patients represented 18% of the study
cohort in Australia, 9% in Canada, 56% in New Zealand, and
3% in the United States. With the exception of New Zealand,
there were significantly fewer men and more women in the
indigenous cohorts when compared with the non-indigenous
cohorts. In all four countries, indigenous patients were
significantly more likely to have a body mass index (BMI)
greater than 30 kg/m2 and to have diabetes than whites. There
were significantly higher rates of ischemic heart disease
among indigenous patients in Australia and New Zealand,
and higher rates of peripheral vascular disease among
indigenous patients in all four countries. The rates of chronic
lung disease and smoking were significantly lower in
indigenous patients in the United States, and higher in
Australia and New Zealand. Indigenous patients were
significantly more likely to smoke in Australia, Canada, and
New Zealand, but less likely to smoke in the United States.
In all four countries, indigenous patients had significantly
lower crude transplant rates per 100 person-years than
white patients (Table 2). Unadjusted transplant rates for
indigenous recipients were different among the countries
(Po0.01). Disparities in access to transplantation were
observed from both living and deceased donor sources. The
proportion of transplants from living donors was lower
among indigenous than among white transplant recipients in
Australia (21.9 vs 39.2%), New Zealand (34.2 vs 42.1%), and
the United States (36.8 vs 44.2%). In contrast, the proportion
of transplants from living donors was slightly higher for
indigenous than for white recipients in Canada (39.5 vs
37.7%) (Table 2).
Table 3 displays unadjusted and adjusted hazard ratios
(HRs) for renal transplantation overall and by donor type for
indigenous patients relative to white patients. Unadjusted
HRs for renal transplantation overall were 0.23 (CI 0.19–0.28)
in Australia, 0.33 (CI 0.26–0.36) in Canada, 0.15 (CI
0.13–0.19) in New Zealand, and 0.42 (CI 0.36–0.42) in the
United States. Age, sex, and comorbid conditions explained
only a small portion of these disparities, as adjustment for
these variables changed the respective HR in each country
only minimally. In each country, disparities in access were
similar for both deceased and living donor transplants
(Table 3).
Table 4 presents median waiting times overall and by
donor type for indigenous compared with white patients. In
all four countries, indigenous patients had significantly
longer overall median waiting times (Po0.01) when
compared with white patients. Indigenous recipients waited
Table 1 | Demographic and clinical characteristics of indigenous and white patients in Australia, Canada, New Zealand, and the
United States
Australia Canada New Zealand United States
Country White Indigenous White Indigenous White Indigenous White Indigenous
N (%) 8058 (81.9) 1779 (18.1) 16,336 (90.8) 1650 (9.2) 1216 (43.9) 1555 (56.1) 274,125 (97.2) 7788 (2.8)
Age (N (%))
18–29 years 819 (10.6) 114 (6.4)** 1109 (6.8) 151 (9.2)** 119 (9.8) 108 (6.9)** 16,870 (6.1) 404 (5.2)**
30–44 years 1987 (24.7) 522 (29.3)** 3817 (23.4) 346 (20.9)** 319 (26.2) 282 (18.1)** 57,454 (21.0) 1584 (20.3)**
45–65 years 5252 (64.7) 1143 (62.7)** 11,410 (69.8) 1153 (69.9) 778 (63.9) 1165 (74.9)** 199,801 (72.9) 5800 (74.5)**
Gender (N (%))
Male 4919 (61.0) 824 (46.3)** 10,136 (62.1) 806 (48.9)** 740 (59.8) 873 (55.2)* 157,828 (57.6) 3846 (49.4)**
Female 3139 (38.9) 955 (53.7)** 6200 (37.9) 844 (51.1)** 476 (39.1) 682 (43.8)* 116,295 (42.4) 3942 (50.6)**
Body mass index (N (%))
o18.5mg/m2 317 (3.9) 92 (5.2)** 538 (3.7) 30 (2.1)** 37 (3.0) 13 (0.8)** 12,904 (5.2) 266 (3.7)**
18.5–24.9mg/m2 3276 (40.9) 599 (33.9)** 5548 (38.4) 405 (27.7)** 536 (44.4) 269 (17.5)** 85,028 (34.1) 2101 (29.0)**
25–29.9mg/m2 2555 (31.9) 520 (29.5)** 4309 (29.9) 511 (35.0)** 394 (32.6) 493 (32.0)** 69,372 (27.9) 2247 (31.1)**
X30mg/m2 1849 (23.1) 522 (31.3)** 4038 (27.9) 514 (35.2)** 240 (19.9) 763 (49.6)** 81,698 (32.8) 2616 (36.2)**
Diabetes (N (%)) 2255 (27.9) 1293 (72.7)** 5840 (35.8) 1011 (61.3)** 278 (22.9) 1072 (68.9)** 122,823 (44.8) 5122 (65.8)**
Cerebrovascular disease (N (%)) 509 (6.3) 147 (8.3)* 1272 (8.6) 147 (9.5) 74 (6.1) 117 (7.5) 16,541 (6.0) 481 (6.2)
Ischemic heart disease (N (%)) 1514 (18.9) 429 (24.1)** 2586 (15.7) 256 (15.5) 190 (15.6) 329 (21.2)** 54,134 (19.7) 1414 (18.2)**
Peripheral vascular disease (N (%)) 1081 (13.4) 315 (17.7)** 2819 (17.3) 397 (24.1)** 144 (11.8) 288 (18.5)** 32,240 (11.8) 1235 (15.9)**
Chronic lung disease (N (%)) 866 (10.7) 253 (14.2)** 1225 (7.5) 106 (6.4) 103 (8.5) 276 (17.8)** 13,345 (4.9) 217 (2.8)**
Current smoker (N (%)) 1272 (15.8) 472 (26.5)** 2993 (18.3) 368 (22.3)** 197 (16.2) 384 (24.7)** 20,139 (7.3) 450 (5.8)**
*Po0.05.
**Pp0.01.
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longest for deceased donor transplants in the United States
(3 years) and shortest in Canada (2.5 years). Waiting times
for living donor transplants were significantly longer for
indigenous compared with white patients in Australia (2.7 vs
0.7 years; Po0.01), Canada (1.6 vs 0.8 years; Po0.01),
New Zealand (1.2 vs 0.6 years; P¼ 0.01), and the United
States (1.2 vs 0.6 years; Po0.01).
The cumulative incidence curves for time to first renal
transplant (in years) for indigenous and white patients in
each country are displayed in Figure 1. Indigenous patients in
all four countries had similar curves showing lower
cumulative incidence of renal transplantation when com-
pared with whites. White patients in the United States had
the lowest cumulative incidence of first renal transplants
overall, followed by Canada, Australia, and New Zealand,
respectively.
DISCUSSION
To our knowledge, this study is the first multinational
evaluation of indigenous access to renal transplantation using
similar methods to adjust for comparable variables from
national renal registries over identical periods. Despite
indigenous populations in each country bearing a signifi-
cantly heavier burden of ESKD than whites, indigenous
people on dialysis are undergoing renal transplantation at less
than half the rate of white patients in their respective
countries. Notwithstanding substantial differences in the
health care systems, renal transplant programs and indige-
nous models of health care delivery in each country, the
disparities in renal transplant rates for indigenous people are
strikingly similar in magnitude across all four countries.
Our study provides several important insights regarding
access to renal transplantation in the four countries studied.
Table 2 | Crude transplant ratesa for indigenous and white patients in Australia, Canada, New Zealand, and the United States
All transplants Deceased donor Living donor Living donor source
Country Ethnicity Unadjusted rates (95% CI) Unadjusted rates (95% CI) Unadjusted rates (95% CI) (% of total)
Australia Indigenous 3.3 (2.8–3.8) 2.6 (2.2–3.0) 0.7 (0.5–0.9) 21.9
White 14.8 (14.3–15.3) 8.9 (8.6–9.4) 5.8 (5.4–6.0) 39.2
Canada Indigenous 3.8 (3.3–4.3) 2.3 (1.8–2.6) 1.5 (1.2–1.8) 39.5
White 11.8 (11.5–12.1) 7.2 (6.9–7.4) 4.6 (4.4–4.8) 37.7
New Zealand Indigenous 2.8 (2.4–3.2) 1.8 (1.5–2.2) 0.9 (0.7–1.2) 34.2
White 19.5 (17.8–21.0) 11.3 (10.1–12.4) 8.2 (7.1–9.4) 42.1
United States Indigenous 4.1 (3.8–4.3) 2.6 (2.4–2.8) 1.4 (1.3–1.6) 36.8
White 10.4 (10.3–10.4) 5.8 (5.7–5.8) 4.5 (4.4–4.6) 44.2
CI, confidence interval.
aRates are calculated per 100 patient-years.
Table 3 | Unadjusted and adjusted hazard ratios for indigenous patients relative to white patients in Australia, Canada,
New Zealand, and the United States
All transplants Deceased donor Living donor
Country
Unadjusted HR
(95% CI)
Adjusteda HR
(95% CI)
Unadjusted HR
(95% CI)
Adjusteda
HR (95% CI)
Unadjusted HR
(95% CI)
Adjusteda
HR (95% CI)
Australia 0.23 (0.20–0.26) 0.23 (0.19–0.27) 0.29 (0.24–0.33) 0.32 (0.27–0.37) 0.15 (0.10–0.19) 0.18 (0.13–025)
Canada 0.33 (0.28–0.37) 0.34 (0.29–0.40) 0.31 (0.26–0.37) 0.31 (0.26–0.37) 0.35 (0.28–0.43) 0.39 (0.30–0.49)
New Zealand 0.15 (0.12–0.18) 0.23 (0.19–0.28) 0.15 (0.13–0.18) 0.22 (0.17–0.28) 0.14 (0.10–0.18) 0.26 (0.18–0.37)
United States 0.42 (0.40–0.45) 0.44 (0.42–0.47) 0.46 (0.43–0.49) 0.49 (0.45–0.53) 0.37 (0.33–0.41) 0.40 (0.36–0.44)
CI, confidence interval; HR, hazard ratio.
aAdjusted for age, sex, primary cause of end-stage kidney disease, year of diagnosis, comorbidities (diabetes, cerebrovascular disease, ischemic heart disease, peripheral
vascular disease, chronic lung disease, and current smoking), and region.
Table 4 |Median renal transplant wait times in years by country among transplant recipients
All transplants Deceased donor Living donor
Country Ethnicity Median (years) Interquartile range Median (years) Interquartile range Median (years) Interquartile range
Australia White 1.5 0.6–2.9 2.1 1.1–3.5 0.7 0.1–1.7
Indigenous 2.4 1.3–3.9 2.6 1.5–3.6 2.7 1.8–4.3
Canada White 1.5 0.6–2.7 1.9 1.0.3.3 0.8 0.2–1.6
Indigenous 2.1 1.2–3.5 2.5 1.5–3.9 1.6 0.9–2.6
New Zealand White 1.2 0.4–2.4 1.7 0.9–2.9 0.6 0.0–1.6
Indigenous 2.2 1.2–3.6 2.7 1.9–4.2 1.2 0.3–2.2
United States White 1.1 0.3–2.4 1.8 0.8–3.2 0.6 0.0–1.3
Indigenous 2.1 1.1–3.8 3.0 1.6–4.4 1.2 0.5–2.0
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First, the disparity in access to transplantation for indigenous
patients in all four countries is significant for both deceased
and living donor kidneys. Second, access to a first renal
transplant for whites is poorest in the United States, followed
by Canada, Australia, and New Zealand, respectively, parti-
cularly for deceased donor kidneys. As a result, the magni-
tude of disparity observed for indigenous patients, relative to
white patients, between the countries is largely driven by the
differences in white access to renal transplantation within
each country. Hence, in the United States, utilization of
renal transplants looks relatively better for Native Americans
in comparison with the other countries studied. This is
because of the low overall renal transplant rates among
white Americans in comparison with Australia, Canada,
and New Zealand.
Third, access to living donor kidneys is relatively better for
indigenous patients in Canada and the United States than in
Australia and New Zealand.
Disparities in living donor transplantation are concerning
because this option is an increasingly important determinant
of transplant access in the context of a global shortage of
deceased donor kidneys. Within indigenous communities,
awareness of living donor transplants as a treatment option,
and the medical suitability of relatives and community
members for donation are key issues to be addressed.
A number of potential mediators may contribute to low
indigenous transplant rates, including language barriers,
patient preferences, health practitioners’ attitudes,19 and the
lack of culturally appropriate patient education programs.
However, evidence regarding the relative importance of
these factors remains scant. To our knowledge, culturally
appropriate educational materials regarding kidney trans-
plantation, specifically targeted to preferred ways of com-
municating and levels of health literacy of indigenous
patients, have not been developed and implemented.
Geographical remoteness has also been suggested as a factor
associated with lower transplantation rates, but the evidence
on this point is mixed.20,21
Other potential barriers for indigenous patients include
delayed referral for transplant evaluation22,23 and delays from
initial referral to wait-listing,15,17,24 as reflected in the near
absence of preemptive transplants among indigenous patients
in our study. All the countries studied have their own
particular renal transplant organ allocation systems. In
general, however, organ allocation among these systems is
prioritized similarly by patient waiting time with immune
matching carrying relatively less weight. Once patients have
been successfully wait-listed, transplant allocation algorithms
that favor higher levels of HLA-matching above waiting time
will reduce access for patients from ethnic minorities, as
deceased donors kidneys are predominantly drawn from the
majority white population.25,26 In addition, institutional bias
or racism may impede indigenous patients’ access to renal
transplantation. People with complex, chronic diseases, such
as kidney disease, must negotiate often fragmented health
care systems to access necessary care.27 Among the four
countries studied, the Indian Health Service of the United
States provides the most comprehensive indigenous health
care system, and it also funds a substantial component of
services managed by Indian tribes. Nonetheless, the presence
of the Indian Health Service and tribal health councils in the
United States is not associated with substantially better access
to renal transplantation for American Indians and Alaskan
Natives, probably because these organizations are mainly
focused on primary and secondary care, and often face
restricted access to tertiary services such as renal transplanta-
tion and major cardiac procedures.12,15 Australia, Canada,
and New Zealand have federally managed indigenous health
agencies, and each of these countries has developed some
community-controlled health services to improve access for
indigenous patients. As in the United States, however, renal
transplantation is a highly specialized procedure provided in
tertiary centers that are not focused on indigenous patients.
Therefore, communication across indigenous and non-
indigenous health services is crucial to support indigenous
patients’ access to renal transplantation.
Our study has several strengths and limitations. Strengths
of our study include the large inclusive cohorts of patients
and the consistent adjustment for relevant clinical variables
across the four countries. However, we were not able to verify
the accuracy of indigenous designations or determine
precisely how much time indigenous patients spent on
transplant waiting lists (in both active and inactive status
categories). In addition, we did not have access to accurate
information regarding residence location of study patients in
all registry data sets. This would have allowed us to address
the possibility that a relationship exists between rural
residence location and racial identity (indigenous or not)
that impacts on renal transplant utilization in our study
groups. This would have considerably strengthened the study.
Lastly, we were unable to obtain data regarding clinical
characteristics, such as HLA matching, from all registries,
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Figure 1 |Proportions of indigenous and white patients
receiving renal transplant by country within 5 years after
onset of renal replacement therapy. Note: curves start above
zero for whites because of the higher proportion of preemptive
renal transplants within this group.
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which would provide useful information for further analyses
relating to organ allocation algorithms.
Substantial disparities in access to renal transplantation
persist for indigenous people with ESKD across the diverse
health care systems of Australia, Canada, New Zealand, and
the United States. These findings suggest that reduced access
may be strongly influenced by social determinants, operating
beyond the confines of the respective health systems. Poverty
and lower levels of educational attainment have been shown
to reduce engagement in health care and to disproportio-
nately affect indigenous populations. Without knowledge of
barriers within and beyond health systems, success in
improving access to renal transplantation, and other effective
medical and surgical services for indigenous people will
remain elusive.
METHODS
Data sources
We analyzed data from the respective national ESKD registries,
including the Australia and New Zealand Dialysis and Transplant
Registry (ANZDATA),28 Canadian Organ Replacement Register
(CORR)5 of the Canadian Institute for Health Information, and
the United States Renal Data System (USRDS).29 ANZDATA and
CORR are voluntary registries that seek participation of all renal
units providing dialysis and transplant services. ANZDATA includes
essentially all patients with ESKD in Australia and New Zealand,
whereas CORR includes over 80% of such patients in Canada. The
USRDS has included all patients with ESKD in the United States
since May 1995, because the Medicare End-Stage Renal Disease
Program requires a Medicare Evidence form to be submitted for all
patients regardless of their insurance and eligibility status.
A complete de-identified dataset of requested variables was
acquired from each of the respective renal registries, and analyzed at
the Canadian Institute for Health Information in Toronto, Canada.
The study protocol was approved by the Research Ethics Board of
Queen’s University, the Human Studies Committee of Harvard
Medical School and the Ethics Committee of the Sydney South
Western Area Health Service in Sydney, Australia.
Study population
We examined data for all indigenous patients in Australia, Canada,
New Zealand, and the United States who initiated maintenance
dialysis for ESKD from 1 January 1995 through to 31 December 2005.
Indigenous people were identified as Aboriginal Australians and
Torres Strait Islanders in Australia; Maori, Samoans, Tongans, Pacific
People, and Cook Islanders in New Zealand; Aboriginal people
(including First Nations, Me´tis, and Inuit) in Canada; and American
Indians and Alaska Natives in the United States. The majority
population (termed ‘white’ in the current analysis) was designated
‘white’, ‘Caucasian’, or ‘Caucasoid’ in individual registries. Approxi-
mately 10% of patients in each country were missing race/ethnicity
data and were therefore excluded, as were patients of other racial
groups. We restricted our analysis to adult patients aged 18–64 years at
initiation of dialysis, because older patients are less likely to be
clinically appropriate for renal transplantation.
Study variables
Variables extracted from each national renal registry included
patients’ age, sex, primary renal diagnosis, comorbid conditions,
height, weight, smoking status, and region of initial dialysis
treatment. Race is reported to each registry by participating clinical
facilities, on the basis of information recorded in patients’ medical
records. BMI (kg/m2) was categorized according to World Health
Organization criteria as underweight (BMI o18.5 kg/m2), normal
weight (BMI 18.5–24.9 kg/m2), overweight (BMI 25.0–29.9 kg/m2),
and obese (BMI X30.0 kg/m2).30 Comorbid conditions recorded
by each registry at the onset of ESKD included diabetes mellitus,
ischemic heart disease (myocardial infarction or angina), peripheral
vascular disease, cerebrovascular disease, chronic obstructive
pulmonary disease, and current smoking.
Analysis
The demographic and clinical characteristics of indigenous
and white patients were compared within each country
using the Pearson’s w2-test. The unadjusted transplant rates per
100 patient-years of treatment were calculated for indigenous
and white patients in each country, with renal transplantation
defined as a first living or deceased donor transplant. Crude
transplant rates were compared between countries (with the
United States as the reference group) using a Poisson model.
Patients were followed up to the date of first renal transplant
or to 31 December 2006 for Australia, Canada, and New Zealand
with the exception of the United States, wherein follow-up was
until 30 September 2006. Patients were censored at the date
of death.
Cox proportional hazards regression models were used to
compare the adjusted likelihood of renal transplantation from
living and/or deceased donors for indigenous patients relative to
white patients in each country, controlling for the demographic and
clinical variables listed above. Median transplant wait times were
calculated overall and by donor type from the initiation of renal
replacement therapy to renal transplantation for indigenous and
white patients in each country using the Wilcoxon rank-sum test.
Cumulative incidence curves for renal transplantation were
produced for indigenous vs white patients in each of the four
countries.
SAS statistical software version 8.2 (Cary, North Carolina) was
used for all analyses. Two-tailed P-values or 95% confidence
intervals are presented for all statistical comparisons of indigenous
and white patients.
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